Cardiovascular drugs rise near top in Open Payments
Candace Stuart | January 08, 2015 | Cardiovascular Business | Economics

Drug makers Bristol-Myers Squibb and Pfizer spent almost $8 million to promote the novel oral anticoagulant Eliquis to physicians, according to an analysis by ProPublica of the Open Payments database. Eliquis, or apixaban, was the second highest drug on the spending list, with AstraZeneca’s Brilinta (ticagrelor) placing third.

The diabetes drug Victoza by Novo Nordisk ranked first. The analysis appeared in the New York Times “Upshot” section.

Analyzing drugs that are most promoted to doctors

Candace Stuart, Contributor

Related Content

Cardiologists, thoracic surgeons applaud FTC’s ban of most noncompete clauses
Why the business side of cardiology was a key focus at ACC.24
Motivation helps heart patients stay active
New Jersey cardiologist faces up to 10 years in prison for $1.9M fraud scheme
Cardiologist salary update: Compensation jumps to $525K per year, No. 3 among all specialties
The growing shortage or general cardiologists and recruiting crisis in rural America

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Radiology Business
Philips launches new AI-enabled CT scanner aimed at cardiology at ECR 2024

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Design by Adaptive Theme
Trimed Popup
Trimed Popup